Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Q4 Pharma Earnings Preview: J&J, Bristol And AbbVie

Executive Summary

Johnson & Johnson has solid growth drivers in pharmaceuticals, but still faces an overhang related to talc controversy; Bristol's call will be dominated by the just-announced Celgene acquisition; and AbbVie will face questions about its cancer plans after expensive failure with Rova-T.

Advertisement

Related Content

Verona Investors Gasp As Lead Asset Misses Main Endpoint In COPD Trial
AbbVie’s Business Development, Cancer Plans Not Put Off By Stemcentrx Disappointments
Tizona Lands AbbVie Cancer R&D Deal As New CEO Takes Control
Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
J&J Doing Damage Control Following Reuters Report On Asbestos ‘Lurking’ In Johnson’s Powder
After Imbruvica Passes Chemo-Free Tests, Shorter Duration Regimens Could Be Next Value-Adds
AbbVie Hit Harder By EU Humira Biosimilars Than Projected
Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity
A First For Prostate Cancer: Janssen's Erleada Approved For Non-Metastatic Patients

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124505

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel